RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. METHODS: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. METHODS: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
Authors: John R Hurst; Gavin C Donaldson; Wayomi R Perera; Tom M A Wilkinson; John A Bilello; Gerry W Hagan; Rupert S Vessey; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2006-06-23 Impact factor: 21.405
Authors: Nicholas R Anthonisen; Melissa A Skeans; Robert A Wise; Jure Manfreda; Richard E Kanner; John E Connett Journal: Ann Intern Med Date: 2005-02-15 Impact factor: 25.391
Authors: Victor Pinto-Plata; John Toso; Kwan Lee; Daniel Park; John Bilello; Hana Mullerova; Mary M De Souza; Rupert Vessey; Bartolome Celli Journal: Thorax Date: 2007-03-13 Impact factor: 9.139
Authors: J Vestbo; W Anderson; H O Coxson; C Crim; F Dawber; L Edwards; G Hagan; K Knobil; D A Lomas; W MacNee; E K Silverman; R Tal-Singer Journal: Eur Respir J Date: 2008-01-23 Impact factor: 16.671
Authors: S F P Man; L Xing; J E Connett; N R Anthonisen; R A Wise; D P Tashkin; X Zhang; R Vessey; T G Walker; B R Celli; D D Sin Journal: Eur Respir J Date: 2008-09-17 Impact factor: 16.671
Authors: Sergei P Atamas; Irina G Luzina; Jung Choi; Natalya Tsymbalyuk; Nicholas H Carbonetti; Ishwar S Singh; Maria Trojanowska; Sergio A Jimenez; Barbara White Journal: Am J Respir Cell Mol Biol Date: 2003-06-12 Impact factor: 6.914
Authors: Raminder Aul; Jane Armstrong; Annelyse Duvoix; David Lomas; Brian Hayes; Bruce E Miller; Chris Jagger; Dave Singh Journal: Br J Clin Pharmacol Date: 2012-12 Impact factor: 4.335
Authors: Salim Merali; Carlos A Barrero; Russell P Bowler; Diane Er Chen; Gerard Criner; Alan Braverman; Samuel Litwin; Anthony Yeung; Steven G Kelsen Journal: COPD Date: 2013-10-10 Impact factor: 2.409
Authors: Michael D Weiden; Sophia Kwon; Erin Caraher; Kenneth I Berger; Joan Reibman; William N Rom; David J Prezant; Anna Nolan Journal: Semin Respir Crit Care Med Date: 2015-05-29 Impact factor: 3.119
Authors: Bushra Naveed; Michael D Weiden; Sophia Kwon; Edward J Gracely; Ashley L Comfort; Natalia Ferrier; Kusali J Kasturiarachchi; Hillel W Cohen; Thomas K Aldrich; William N Rom; Kerry Kelly; David J Prezant; Anna Nolan Journal: Am J Respir Crit Care Med Date: 2011-11-17 Impact factor: 21.405
Authors: Hye Yun Park; Andrew Churg; Joanne L Wright; Yuexin Li; Sheena Tam; S F Paul Man; Donald Tashkin; Robert A Wise; John E Connett; Don D Sin Journal: Am J Respir Crit Care Med Date: 2013-12-15 Impact factor: 21.405